The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells

Cancer Letters

Volumn 273, Issue 1, 2009, Pages 127-139

  Nevo, Ido ^a   Sagi Assif, Orit ^a   Meshel, Tsipi ^a   Ben Baruch, Adit ^a   Jöhrer, Karin ^b   Greil, Richard ^b   Trejo, Leonor E Leider ^a   Kharenko, Oleg ^a   Feinmesser, Meora ^c   Yron, Ilana ^a   Witz, Isaac P ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

CX3CL1; CX3CR1; Fractalkine; Human bone marrow endothelial cells; Neuroblastoma

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; CXCL1 CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLIGONUCLEOTIDE; PROTEIN KINASE B; PROTEIN KINASE C;

ARTICLE; BONE MARROW CELL; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BLOTTING, WESTERN; BONE MARROW CELLS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CX3CL1; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTEIN KINASE C; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 56349147729     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.029     Document Type: Article

References (60)

1. Brodeur G.M., and Castleberry R.P. Chapter 29: Neuroblastoma. In: Pizzo P.A., and Poplack D.G. (Eds). Principles and Practice of Pediatric Oncology (1997), Lippincott-Raven Publishers, Philadelphia, PA 761-783
2. Vasudevan S.A., and Nuchtern J.G. Gene profiling of high risk neuroblastoma. World J. Surg. 29 (2005) 317-324
3. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3 (2003) 203-216
4. Brodeur G.M. Chapter 24: Neuroblastoma and other peripheral neuroectodermal tumors. In: Fernbach D.J., and Vietti T.J. (Eds). Clinical Pediatric Oncology (1991), Mosby Year Book, St. Louis, MO 437-464
5. Geminder H., Sagi-Assif O., Goldberg L., Meshel T., Rechavi G., Witz I.P., and Ben-Baruch A. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol. 167 (2001) 4747-4757
6. Nevo I., Sagi-Assif O., Meshel T., Geminder H., Goldberg-Bittman L., Ben-Menachem S., Shalmon B., Goldberg I., Ben-Baruch A., and Witz I.P. The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. Immunol. Lett. 92 (2004) 163-169
7. Goldberg-Bittman L., Sagi-Assif O., Meshel T., Nevo I., Levy-Nissenbaum O., Yron I., Witz I.P., and Ben-Baruch A. Cellular characteristics of neuroblastoma cells: regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 29 (2005) 105-117
8. Kulbe H., Levinson N.R., Balkwill F., and Wilson J.L. The chemokine network in cancer-much more than directing cell movement. Int. J. Dev. Biol. 48 (2004) 489-496
9. Ara T., and DeClerck Y.A. Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev. 25 (2006) 645-657
10. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3 (2003) 453-458
11. Witz I.P. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev. 27 (2008) 19-30
12. Witz I.P., and Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Lett. (2006)
13. Pan Y., Lloyd C., Zhou H., Dolich S., Deeds J., Gonzalo J.A., Vath J., Gosselin M., Ma J., Dussault B., Woolf E., Alperin G., Culpepper J., Gutierrez-Ramos J.C., and Gearing D. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387 (1997) 611-617
14. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., and Schall T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature 385 (1997) 640-644
15. Garton K.J., Gough P.J., Blobel C.P., Murphy G., Greaves D.R., Dempsey P.J., and Raines E.W. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276 (2001) 37993-38001
16. Muehlhoefer A., Saubermann L.J., Gu X., Luedtke-Heckenkamp K., Xavier R., Blumberg R.S., Podolsky D.K., MacDermott R.P., and Reinecker H.C. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J. Immunol. 164 (2000) 3368-3376
17. Ludwig A., Berkhout T., Moores K., Groot P., and Chapman G. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J. Immunol. 168 (2002) 604-612
18. Papadopoulos E.J., Sassetti C., Saeki H., Yamada N., Kawamura T., Fitzhugh D.J., Saraf M.A., Schall T., Blauvelt A., Rosen S.D., and Hwang S.T. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur. J. Immunol. 29 (1999) 2551-2559
19. Lucas A.D., Chadwick N., Warren B.F., Jewell D.P., Gordon S., Powrie F., and Greaves D.R. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am. J. Pathol. 158 (2001) 855-866
20. Yoshikawa M., Nakajima T., Matsumoto K., Okada N., Tsukidate T., Iida M., Otori N., Haruna S., Moriyama H., Imai T., and Saito H. TNF-alpha and IL-4 regulate expression of fractalkine (CX3CL1) as a membrane-anchored proadhesive protein and soluble chemotactic peptide on human fibroblasts. FEBS Lett. 561 (2004) 105-110
21. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., Kakizaki M., Takagi S., Nomiyama H., Schall T.J., and Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91 (1997) 521-530
22. Umehara H., Bloom E.T., Okazaki T., Nagano Y., Yoshie O., and Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 34-40
23. Goda S., Imai T., Yoshie O., Yoneda O., Inoue H., Nagano Y., Okazaki T., Imai H., Bloom E.T., Domae N., and Umehara H. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J. Immunol. 164 (2000) 4313-4320
24. Harrison J.K., Jiang Y., Chen S., Xia Y., Maciejewski D., McNamara R.K., Streit W.J., Salafranca M.N., Adhikari S., Thompson D.A., Botti P., Bacon K.B., and Feng L. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. USA 95 (1998) 10896-10901
25. Combadiere C., Salzwedel K., Smith E.D., Tiffany H.L., Berger E.A., and Murphy P.M. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J. Biol. Chem. 273 (1998) 23799-23804
26. Deiva K., Geeraerts T., Salim H., Leclerc P., Hery C., Hugel B., Freyssinet J.M., and Tardieu M. Fractalkine reduces N-methyl-d-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation. Eur. J. Neurosci. 20 (2004) 3222-3232
27. Andre F., Cabioglu N., Assi H., Sabourin J.C., Delaloge S., Sahin A., Broglio K., Spano J.P., Combadiere C., Bucana C., Soria J.C., and Cristofanilli M. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann. Oncol. 17 (2006) 945-951
28. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
29. Ohta M., Tanaka F., Yamaguchi H., Sadanaga N., Inoue H., and Mori M. The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int. J. Oncol. 26 (2005) 41-47
30. Shulby S.A., Dolloff N.G., Stearns M.E., Meucci O., and Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 64 (2004) 4693-4698
31. Neumark E., Sagi-Assif O., Shalmon B., Ben-Baruch A., and Witz I.P. Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int. J. Cancer 106 (2003) 879-886
32. Zipin A., Israeli-Amit M., Meshel T., Sagi-Assif O., Yron I., Lifshitz V., Bacharach E., Smorodinsky N.I., Many A., Czernilofsky P.A., Morton D.L., and Witz I.P. Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells. Cancer Res. 64 (2004) 6571-6578
33. Rood P.M., Calafat J., von dem Borne A.E., Gerritsen W.R., and van der Schoot C.E. Immortalisation of human bone marrow endothelial cells: characterisation of new cell lines. Eur. J. Clin. Invest. 30 (2000) 618-629
34. Matsumiya T., Imaizumi T., Fujimoto K., Cui X., Shibata T., Tamo W., Kumagai M., Tanji K., Yoshida H., Kimura H., and Satoh K. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp. Cell Res. 269 (2001) 35-41
35. Wu C., Keivens V.M., O'Toole T.E., McDonald J.A., and Ginsberg M.H. Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix. Cell 83 (1995) 715-724
36. Fukuda S., Broxmeyer H.E., and Pelus L.M. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis. Blood 105 (2005) 3117-3126
37. Kennett R.H., Fairbrother T., Hampshire B., and Bodmer W.F. The specificity of naturally occurring heterophile antibodies in normal rabbit serum. Tissue Antigens 8 (1976) 21-28
38. Chang L., and Karin M. Mammalian MAP kinase signalling cascades. Nature 410 (2001) 37-40
39. Viala E., and Pouyssegur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann. NY Acad. Sci. 1030 (2004) 208-218
40. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
41. Brader S., and Eccles S.A. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90 (2004) 2-8
42. Meucci O., Fatatis A., Simen A.A., and Miller R.J. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc. Natl. Acad. Sci. USA 97 (2000) 8075-8080
43. Homey B., Muller A., and Zlotnik A. Chemokines: agents for the immunotherapy of cancer?. Nat. Rev. Immunol. 2 (2002) 175-184
44. Balkwill F. Chemokine biology in cancer. Semin. Immunol. 15 (2003) 49-55
45. Witz I.P. The involvement of selectins and their ligands in tumor-progression. Immunol. Lett. 104 (2006) 89-93
46. Hundhausen C., Misztela D., Berkhout T.A., Broadway N., Saftig P., Reiss K., Hartmann D., Fahrenholz F., Postina R., Matthews V., Kallen K.J., Rose-John S., and Ludwig A. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102 (2003) 1186-1195
47. Hatori K., Nagai A., Heisel R., Ryu J.K., and Kim S.U. Fractalkine and fractalkine receptors in human neurons and glial cells. J. Neurosci. Res. 69 (2002) 418-426
48. Chapman G.A., Moores K., Harrison D., Campbell C.A., Stewart B.R., and Strijbos P.J. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J. Neurosci. 20 (2000) RC87
49. Xie K., and Huang S. Regulation of cancer metastasis by stress pathways. Clin. Exp. Metastasis 20 (2003) 31-43
50. Castleberry R.P. Consistently investigating the inconsistent nature of neuroblastoma. J. Pediatr. Hematol. Oncol. 21 (1999) 178-180
51. Faure S., Meyer L., Costagliola D., Vaneensberghe C., Genin E., Autran B., Delfraissy J.F., McDermott D.H., Murphy P.M., Debre P., Theodorou I., and Combadiere C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287 (2000) 2274-2277
52. Ancuta P., Moses A., and Gabuzda D. Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditions. Immunobiology 209 (2004) 11-20
53. Liesveld J.L., Rosell K., Panoskaltsis N., Belanger T., Harbol A., and Abboud C.N. Response of human CD34+ cells to CXC, CC, and CX3C chemokines: implications for cell migration and activation. J. Hematother. Stem Cell Res. 10 (2001) 643-655
54. Ancuta P., Rao R., Moses A., Mehle A., Shaw S.K., Luscinskas F.W., and Gabuzda D. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J. Exp. Med. 197 (2003) 1701-1707
55. Zeng Y., Huebener N., Fest S., Weixler S., Schroeder U., Gaedicke G., Xiang R., Schramm A., Eggert A., Reisfeld R.A., and Lode H.N. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res. 67 (2007) 2331-2338
56. McDermott D.H., Fong A.M., Yang Q., Sechler J.M., Cupples L.A., Merrell M.N., Wilson P.W., D'Agostino R.B., O'Donnell C.J., Patel D.D., and Murphy P.M. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest. 111 (2003) 1241-1250
57. Rofstad E.K. Microenvironment-induced cancer metastasis. Int. J. Radiat. Biol. 76 (2000) 589-605
58. Nutt J.E., and Lunec J. Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells. Eur. J. Cancer 32A (1996) 2127-2135
59. Yamashita K., Imaizumi T., Hatakeyama M., Tamo W., Kimura D., Kumagai M., Yoshida H., and Satoh K. Effect of hypoxia on the expression of fractalkine in human endothelial cells. Tohoku J. Exp. Med. 200 (2003) 187-194
60. Mantovani A., Locati M., Vecchi A., Sozzani S., and Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 22 (2001) 328-336